Cargando…
Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT
The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were gen...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515525/ https://www.ncbi.nlm.nih.gov/pubmed/32791030 http://dx.doi.org/10.1080/15384047.2020.1796195 |